The increased number of NSCLC patients at PD harboring CTCs positive in PD-L1 suggests a theoretical background for immune checkpoint inhibition (ICI) therapy in EGFRm NSCLC patients resistant to osimertinib (73). This evidence concerns the gene CD274 and non-small cell lung carcinoma.